A Phase 1/2, Open-label, Multicenter Trial to Assess the Safety and Efficacy of ARD103 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Status: Not yet recruiting

Phase of Trial: Phase I/II

Latest Information Update: 15 Nov 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs ARD 103 (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary)
Indications Acute myeloid leukaemia; Myelodysplastic syndromes
Focus Adverse reactions; Therapeutic Use
Sponsors ARCE Therapeutics

15 Nov 2024 New trial record
18 Oct 2024 According to an Arce therapeutics media release, ARD103 CAR-T has has passed the human investigational new drug review (IND) of the USFDA and has been approved by the U.S. FDA for Phase I/II clinical trials to treat the rare disease acute myeloid leukemia. It is expected to start clinical trials in the Q1 2025 and be included in the acceptance.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com